Multiple factors are negatively impacting the compounded Semaglutide market. Insurance coverage for GLP-1s, like Wegovy, still varies widely from plan to plan. Demand for Semaglutide and other GLP-1s ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss ...

PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

Novo Nordisk alleges the clinics unauthorized use of compounded drugs containing semaglutide means those medications have not been evaluated by the FDA — further suggesting the medication has ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy. Novo Nordisk has announced ...

The supply of GLP-1 drugs for weight loss and diabetes treatment was expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients ...

and Thursday is the final cutoff date for compounded semaglutide.Thousands – and perhaps millions – of patients have been using these compounded GLP-1 receptor agonist medications, which are ...

Thursday was the final cut-off for compounded semaglutide. The Outsourcing Facilities Association, a trade group representing compounding pharmacies, challenged the FDA’s decision in court ...